GlassScriptPhysician profile
Serena Beshi
NPI 1407669856
$956.22
in general payments reported to CMS, 2019-2025
27 companies · $956 in 2025
The $956 reported for 2025 was more than what 82% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $956.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $956.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $956.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $153.42 | 2025 | Fintepla, Briviact, Rystiggo |
| Abbvie INC. | $95.69 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $59.08 | 2025 | Hyqvia |
| Lundbeck LLC | $47.53 | 2025 | Vyepti |
| Emd Serono, INC. | $43.40 | 2025 | |
| Alnylam Pharmaceuticals INC. | $42.32 | 2025 | Givlaari |
| Jazz Pharmaceuticals INC. | $39.42 | 2025 | |
| Biogen, INC. | $38.99 | 2025 | Skyclarys |
| Vanda Pharmaceuticals INC. | $36.49 | 2025 | Ponvory |
| Celgene Corporation | $35.79 | 2025 | Zeposia |
| Tg Therapeutics, INC. | $34.54 | 2025 | |
| Csl Behring | $31.16 | 2025 | Hizentra |
| Genzyme Corporation | $26.85 | 2025 | |
| Catalyst Pharmaceuticals, INC. | $25.84 | 2025 | |
| Ani Pharmaceuticals, INC. | $25.42 | 2025 | Purified Cortrophin Gel |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz Pharmaceuticals, LLC | $25.11 | 2025 | Xeomin |
| Vertex Pharmaceuticals Incorporated | $21.92 | 2025 | |
| Axsome Therapeutics, INC. | $21.35 | 2025 | Symbravo |
| Otsuka America Pharmaceutical, INC. | $20.04 | 2025 | Rexulti |
| Servier Pharmaceuticals LLC | $19.36 | 2025 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $18.16 | 2025 | Rexulti |
| Acadia Pharmaceuticals INC | $17.90 | 2025 | Daybue |
| Mallinckrodt Hospital Products INC. | $17.70 | 2025 | Acthar |
| Avadel Cns Pharmaceuticals, LLC | $16.34 | 2025 | Lumryz |
| Pfizer INC. | $14.90 | 2025 | |
| Alexion Pharmaceuticals, INC. | $13.75 | 2025 | Ultomiris |
| Genentech USA, INC. | $13.75 | 2025 | Ocrevus Zunovo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Serena Beshi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.